Table 3.

Median analyte scores for markers that had significant differential abundance between ER‐positive and ER‐negative cases. ER status was determined by the patient pathology report. Q‐values are presented for FDR‐corrected values that account for multiple tests.

Tumor				Stroma
Marker	ER‐positive	ER‐negative	q‐value	Marker	ER‐positive	ER‐negative	q‐value
	Median (IQR)	Median (IQR)			Median (IQR)	Median (IQR)
ER	49.46 (83.21)	3.19 (3.68)	3.7E‐11	ER	5.60 (7.00)	2.12 (0.00)	9.1E‐09
PanCk	514.71 (419.47)	225.88 (271.31)	4.1E‐07	PanCk	30.99 (37.46)	13.11 (12.64)	1.6E‐07
Bcl‐2	30.66 (29.87)	5.95 (8.41)	7.4E‐07	CD14	23.18 (26.72)	55.97 (56.26)	1.2E‐04
Ki‐67	10.53 (11.69)	26.56 (38.69)	1.9E‐05	CD40	3.93 (4.54)	8.89 (10.34)	1.2E‐04
CD45	12.26 (9.62)	21.11 (31.75)	3.4E‐03	β2‐microglobulin	8.14 (7.12)	13.92 (11.75)	9.6E‐04
CD11c	9.34 (5.50)	13.08 (14.8)	3.5E‐03	CD25	2.12 (1.80)	4.63 (3.02)	9.6E‐04
CD14	12.37 (12.03)	24.05 (32.89)	3.5E‐03	CD45	34.34 (39.87)	76.24 (94.88)	9.6E‐04
CD40	2.12 (1.05)	3.92 (5.42)	3.5E‐03	CD127	27.47 (18.86)	38.12 (21.47)	2.9E‐03
CD68	16.67 (10.37)	23.34 (21.67)	7.4E‐03	CD4	10.90 (10.93)	18.19 (19.56)	3.9E‐03
β2‐microglobulin	5.63 (5.41)	10.96 (12.22)	7.6E‐03	CD68	33.53 (25.39)	56.9 (45.60)	3.9E‐03
CD4	5.19 (3.51)	8.12 (6.62)	1.0E‐02	Ki‐67	5.02 (3.49)	8.64 (6.38)	4.8E‐03
EpCAM	68.16 (99.55)	160.71 (134.80)	1.0E‐02	CD45RO	5.03 (4.12)	8.14 (9.40)	5.1E‐03
S100B	5.33 (10.86)	32.85 (128.89)	1.0E‐02	S100B	8.77 (19.23)	28.22 (43.11)	7.1E‐03
OX40L	3.69 (3.01)	4.85 (6.55)	1.2E‐02	CD3	5.65 (6.31)	8.4 (17.43)	8.5E‐03
CD25	3.52 (2.57)	4.91 (4.00)	1.2E‐02	CD11c	20.62 (20.26)	30.52 (23.77)	1.0E‐02
Fibronectin	38.54 (50.70)	28.03 (28.73)	2.0E‐02	CD44	130.01 (147.33)	268.76 (309.84)	1.5E‐02
GZMB	13.88 (9.26)	17.08 (11.11)	2.7E‐02	Fibronectin	186.98 (119.64)	137.65 (109.95)	2.2E‐02
CD8	6.6 (3.69)	8.44 (9.27)	2.9E‐02	OX40L	3.58 (3.17)	4.38 (4.03)	2.2E‐02
CD3	2.12 (0.98)	3.08 (3.88)	3.8E‐02